Clinical Trial Update: Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent [Phase 1]

View source ↗

Summary

Phase 1 trial of activated T-cell therapy with low-dose aldesleukin and sargramostim for advanced ovarian, fallopian tube, or primary peritoneal cancer has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Activated T-cell therapy
• Aldesleukin (interleukin-2)
• sargramostim (sargramostim)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor | Phase 1 | Status: WITHDRAWN